Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients.
Level 4 - case-series / case-control
Ex vivo case-control and postmortem comparative laboratory study
PubMed 16006665 · doi:10.3233/jad-2005-7304
What was done
Immunohistochemical analyses of frontal lobe and hippocampus tissue were performed to examine macrophage infiltration and cytokine/chemokine (IL-1beta, RANTES) expression. Monocytes and macrophages isolated from the blood of Alzheimer's disease (AD) patients and age-matched controls were tested ex vivo for differentiation, amyloid-beta (Abeta) phagocytosis, apoptosis, HLA DR and COX-2 expression, and intracellular cytokine levels.
What was found
No quantitative data, sample sizes, or statistical values are reported in the abstract. Control monocytes differentiated into macrophages and phagocytosed Abeta intracellularly followed by degradation or export. In contrast, AD monocytes exhibited poor differentiation, surface-only Abeta uptake, and apoptosis. AD neutrophils and monocytes abnormally expressed HLA DR and COX-2, and AD patients showed higher intracellular cytokine levels than controls.
Why it matters
This study provides evidence that systemic peripheral innate immune cells, specifically blood-borne macrophages, exhibit impaired amyloid-beta clearance in Alzheimer's disease.
Limits
The abstract provides no sample sizes (n is unknown) and no numerical results or statistical measures. The findings rely on ex vivo laboratory assays and postmortem immunohistochemistry, which cannot determine whether systemic macrophage impairment is a causal driver or a downstream consequence of disease progression.
Cited by
- supports Patients with Alzheimer's disease show a reduced capacity of peripheral blood mononuclear cells/macrophages to phagocytose beta-amyloid, which returns to normal following the Bredesen protocol.